More About Office of Technology Development Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Malme-3M: Human Melanoma Cell Line

SK2009-092

Description

Malme-3M is a malignant human melanoma cell line that displays fibroblast-like morphology and grows in mixed culture (adherent-suspension). This cell line has been shown to be dependent upon micropthalmia-associated transcription factor (MITF) activity for growth and survival. Malme-3M cells form tumors when injected into immunocompromised mice. These cells express mutant B-Raf (V600E) and wildtype N-Ras.

Source

This cell line was established in 1975 from a metastatic site (lung) in a 43-year-old Caucasian male with metastatic melanoma.

Inventors

  • Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
  • Germaine Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
  • Xing F et al. (2012) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 31: 446-457 (PubMed ID: 21725359)
  • Ma J et al. (2013) HER2 as a Promising Target for Cytotoxicity T Cells in Human Melanoma Therapy. PLoS One 8: e73261 (PubMed ID: 24015299)

Comments

Malme-3, a normal skin fibroblast cell line, isolated from the same patient as the Malme-3M melanoma cell line, is also available for licensing.

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

Contact Information

  • For licensing requests: Alexandra Buga, MBA, Licensing Associate, Office of Technology Development, MSK, 646-888-1078, bugaa@mskcc.org
  • For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, weisgarf@mskcc.org

Stage of Development

Ready to use

Indications